COMy 2023 | Using MRD to drive maintenance therapy decisions in patients with myeloma after autoSCT

Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses the use of measurable residual disease (MRD) as a biomarker to assess treatment response in patients with multiple myeloma. Dr Costa first explains that MRD is a strong prognosticator of progression-free survival (PFS) and overall survival (OS), and further notes that MRD can be used to drive therapeutic decisions, particularly regarding the continuation or cessation of lenalidomide maintenance therapy after autologous stem cell transplantation (autoSCT). To conclude, Dr Costa cites studies showing that lower-risk patients with myeloma who achieve and sustain MRD negativity have promising outcomes even in the absence of maintenance therapy. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.